Vivere Oncotherapies
Unmask Cold Tumors
Berkeley, California, US
Vivere Oncotherapies is a bioengineering company developing targeted gene therapies to activate the immune system against "cold" solid tumors that are resistant to existing treatments.
Problem Statement
"Cold" solid tumors, such as colorectal and ovarian cancers, evade immune detection and are resistant to existing immunotherapies like checkpoint inhibitors, creating a lack of effective treatment options.
Core Technology
Proprietary bioengineering platform using gene therapy, viral vector engineering, and immuno-oncology to create targeted therapies for solid tumors.
Key Differentiators
Engineered delivery vehicles capable of selective tumor replication; Multi-antigen immune cell targeting; Expression of therapeutic cargoes to address immunosuppressive tumor environments; Use of directed evolution to create highly specific vectors and genetic cargoes
Clinical Focus
Oncology
Company Info
- Business Model
- Service
- Total Funding
- 10,000,000
- Website
- www.viveretx.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Preclinical validation in colorectal cancer models showing improved tumor distribution, size reduction, and survival. Platform-stage technology targeting solid tumor indications.
MedStartr Index Score
?What do you think of Vivere Oncotherapies?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.